- Home
- PTC vs BBIO Comparison
PTC vs BBIO Comparison
Compare PTC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTC | BBIO |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 15.3B |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PTC | BBIO |
|---|---|---|
| Price | $137.06 | $77.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 25 |
| Target Price | ★ $182.83 | $86.04 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.87 | N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $2,739,226,000.00 | $502,076,000.00 |
| Revenue This Year | $0.43 | $88.16 |
| Revenue Next Year | $6.22 | $74.13 |
| P/E Ratio | $98.28 | ★ N/A |
| Revenue Growth | 19.18 | ★ 126.26 |
| 52 Week Low | $130.89 | $31.77 |
| 52 Week High | $219.69 | $84.94 |
Technical Indicators
Market Signals| Indicator | PTC | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 61.68 |
| Support Level | N/A | $70.65 |
| Resistance Level | $148.00 | $78.20 |
| Average True Range (ATR) | 4.48 | 2.61 |
| MACD | -0.20 | 0.60 |
| Stochastic Oscillator | 36.70 | 80.69 |
Price Performance
Historical ComparisonAbout PTC PTC Inc.
PTC is a US-based global company that offers high-end computer-assisted design, product lifecycle management, and augmented reality solutions that industrial manufacturers commonly use on factory floors. Founded in 1985, PTC is a major player in parametric design and serves some of the world's most well-known equipment manufacturers, such as Caterpillar, Garmin, and Thermo Fisher.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.